Xeris Biopharma Holdings Inc (XERS)
3.405
-0.10
(-2.99%)
USD |
NASDAQ |
Dec 12, 16:00
3.405
0.00 (0.00%)
After-Hours: 17:53
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 507.62M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 82.81% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 2.617 |
Price to Book Value | -- |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -8.166 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 96.22% |
Profile
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect. |
URL | https://www.xerispharma.com |
Investor Relations URL | https://ir.xerispharma.com/ |
HQ State/Province | Illinois |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Small Cap/Blend |
Next Earnings Release | Mar. 06, 2025 (est.) |
Last Earnings Release | Nov. 08, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect. |
URL | https://www.xerispharma.com |
Investor Relations URL | https://ir.xerispharma.com/ |
HQ State/Province | Illinois |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Small Cap/Blend |
Next Earnings Release | Mar. 06, 2025 (est.) |
Last Earnings Release | Nov. 08, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |